NCT03941860 2025-05-23
Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial
National Cancer Institute (NCI)
Phase 3 Completed
National Cancer Institute (NCI)
Hoffmann-La Roche
University of Kansas Medical Center
Memorial Sloan Kettering Cancer Center